Cel Scoliosis affects 2-3% of the world population i.e. about 12 million people in the EU. 20,000 cases of severe scoliosis are reported each year in the EU but less than 3,000 cases ever undergo surgery due to cost and complexity of the surgery. Severe cases of scoliosis are treated by spinal fusion; a major surgical procedure that makes the spine permanently rigid restricting physical activities and permanent arrest of spinal growth. The impact of spinal deformity caused by scoliosis on the quality of life before and after surgery is huge compared with other chronic conditions such as arthritis, chronic obstructive lung disease, diabetes and hypertension.Due to the need for an alternative method for better correction of scoliosis deformities we have developed novel devices and a highly innovative care model involving a safer and significantly less invasive, complete cure which preserves spinal mobility and growth potential. Our solution will result in reduced cost of treatment by over 40% because of shorter hospitalisation, reduced operating time, elimination of additional procedures and lifetime care costs.Spine surgery currently holds a €10.2 billion global market share and is estimated to grow at a compound annual growth rate of 6.9% to reach €17.5 billion by 2022. We aim to capture a market share of 0.1% in 5 years post commercialisation of our project and earn compound revenues of €42.5 million by selling our devices over the same period.In Phase 1 of this project we intend to conduct detailed planning of the testing and design optimisation phases, carry out a market study plan, identify and engage international partners and develop a draft business plan for use upon commercialisation within a period of 6 months.In Phase 2 we will develop an advanced prototype meeting relevant EU and US Medical Devices Directives, demonstrate surgical techniques, rehabilitation strategies, and post-operative procedures and also conduct introductory marketing of our devices. Dziedzina nauki medical and health sciencesclinical medicinerheumatologymedical and health sciencesclinical medicinephysiotherapymedical and health sciencesclinical medicineendocrinologydiabetesmedical and health sciencesclinical medicinesurgerysurgical procedures Program(-y) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Temat(-y) PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Zaproszenie do składania wniosków H2020-SMEInst-2014-2015 Zobacz inne projekty w ramach tego zaproszenia Szczegółowe działanie H2020-SMEINST-1-2014 System finansowania SME-1 - SME instrument phase 1 Koordynator ATC GROUP LIMITED Wkład UE netto € 50 000,00 Adres UNIT 17 PERRYWOOD BUSINESS PARK HONEYCROCK LANE SALFORDS RH1 5JQ REDHILL SURREY Zjednoczone Królestwo Zobacz na mapie MŚP Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant. Tak Region South East (England) Surrey, East and West Sussex East Surrey Rodzaj działalności Private for-profit entities (excluding Higher or Secondary Education Establishments) Linki Kontakt z organizacją Opens in new window Uczestnictwo w unijnych programach w zakresie badań i innowacji Opens in new window sieć współpracy HORIZON Opens in new window Koszt całkowity € 71 429,00
